

What's new...What's next...What to do now

levetiracetam (Keppra®)*

THERAPEUTIC CLASS

- Anticonvulsant

UNITED STATES BRANDED SALES†

- \$ 1 Billion

DOSAGE FORM AND ANTICIPATED AVAILABLE STRENGTHS

- Tablet; 250 mg, 500 mg and 750 mg

LAUNCH DATE‡

- November 4, 2008

MARKET INSIGHT

- Keppra® (UCB, Inc.), the reference brand, is indicated as adjunctive therapy in the treatment of:
 - partial onset seizures in adults and children 4 years of age and older with epilepsy
 - myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy
 - primary generalized tonic clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy
- UCB was granted pediatric exclusivity until January 14, 2009.

SELECTED MEDICATIONS AVAILABLE IN THE CLASS

- Generics (various manufacturers): carbamazepine, divalproex sodium, gabapentin, oxcarbazepine, phenytoin, valproic acid
- Brands: Topamax® (topiramate, Ortho-McNeil Pharmaceutical, Inc.)

ECONOMIC IMPACT

- CVS Caremark estimates that levetiracetam will offer clients Per Member Per Month cost savings, for the remainder of 2008, of \$0.00 to \$0.01, which equates to Per Member Per Year cost savings of \$0.03 to \$0.12.
- For 2009, CVS Caremark estimates Per Member Per Month cost savings of \$0.07 to \$0.10, which equates to Per Member Per Year cost savings of \$0.85 to \$1.14.
- CVS Caremark will continue to monitor the long-term budget effects of levetiracetam's introduction into the pharmaceutical marketplace.

CVS CAREMARK RESPONSE

- CVS Caremark offers publications and Web-based applications to ensure that our clients receive timely information regarding generic medications.
- For more information, call your CVS Caremark account representative.

CVS Caremark encourages the use of generic medications as first-line therapy wherever appropriate.

You can count on CVS Caremark to pursue every opportunity to encourage generic utilization with both physicians and plan participants.

Please Note: This document provides a brief overview of the subject. This review is provided as a reference only and is based in part on information derived from third parties.

* This information is current as of November 11, 2008. The information presented is subject to change and is represented to the best of our knowledge at the time of this publication.

† Industry sales data are from the last twelve months.

‡ A launch date may not reflect the actual availability of this medication. Due to circumstances beyond the control of CVS Caremark, information related to prospective medication launch dates is subject to change without notice. This information should not be solely relied upon for decision-making purposes. This medication is expected to be available in pharmacies within a few days of launch.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

References

- CVS Caremark Generic Contracting Team. • CVS Caremark Internal Pharmacy Budget Impact, Research and Development. • Drugs@FDA. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation and Research. Levetiracetam. <http://www.accessdata.fda.gov/scripts/cder/drugsatfda/>. Accessed November 4, 2008.
- Keppra [package insert]. Smyrna, GA: UCB, Inc.; February 2008. • Mylan Receives Final Approval for First-To-File Generic Version of Antiepileptic Keppra and Launches Immediately. [press release]. Pittsburgh, PA: Mylan Inc; November 4, 2008. <http://mylan.mediaroom.com/index.php?s=43&item=392>. Accessed November 4, 2008.